PREMAL LULLA to Antigens, CD19
This is a "connection" page, showing publications PREMAL LULLA has written about Antigens, CD19.
Connection Strength
1.413
-
The use of chimeric antigen receptor T cells in patients with non-Hodgkin lymphoma. Clin Adv Hematol Oncol. 2018 May; 16(5):375-386.
Score: 0.535
-
Expanding Accessibility to CD19-CAR T Cells: Commercializing a "Boutique" Therapy. Mol Ther. 2017 01 04; 25(1):8-9.
Score: 0.488
-
Cytokine Release Syndrome and Neurotoxicity Following CD19 CAR-T in B-Cell Lymphoma. Transplant Cell Ther. 2025 Jul; 31(7):419-433.
Score: 0.217
-
Checkpoint inhibition and cellular immunotherapy in lymphoma. Hematology Am Soc Hematol Educ Program. 2016 Dec 02; 2016(1):390-396.
Score: 0.121
-
Antitumor efficacy and safety of unedited autologous CD5.CAR T cells in relapsed/refractory mature T-cell lymphomas. Blood. 2024 03 28; 143(13):1231-1241.
Score: 0.050